PRMT5 inhibitors for cancer, sickle cell, and HPFH treatment
Summary
USPTO granted patent US12595262B2 to Merck Sharp & Dohme LLC for PRMT5 inhibitor compounds and methods of treatment for cancer, sickle cell disease, and hereditary persistence of foetal hemoglobin (HPFH). The patent covers 14 claims including compounds A through D and their pharmaceutical salts, esters, and prodrugs.
What changed
USPTO issued patent US12595262B2 to Merck Sharp & Dohme LLC covering PRMT5 (protein arginine methyltransferase 5) inhibitor compounds and their use in treating cancer, sickle cell disease, and hereditary persistence of foetal hemoglobin. The patent includes 14 claims directed to the compounds themselves, pharmaceutical compositions, and methods of treatment.\n\nFor pharmaceutical companies developing oncology or hematology treatments targeting PRMT5, this patent may impact freedom-to-operate considerations. Competitors researching similar PRMT5 inhibitor mechanisms should assess potential infringement risks. The patent does not impose regulatory compliance obligations but establishes proprietary rights that could affect competitive R&D strategies in this therapeutic area.
What to do next
- Review patent claims for freedom-to-operate analysis
- Monitor for related patent applications in therapeutic space
- Evaluate licensing opportunities if applicable
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PRMT5 inhibitors
Grant US12595262B2 Kind: B2 Apr 07, 2026
Assignee
Merck Sharp & Dohme LLC
Inventors
Michelle Machacek, Michael D. Altman, Chunhui Huang, Michael H. Reutershan, David L. Sloman, David J. Witter, Craig R. Gibeau
Abstract
The present invention provides a compound selected from: compounds A, B, C, D and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds disclosed herein, pharmaceutical compositions comprising compounds disclosed herein, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
CPC Classifications
C07D 487/04 C07D 401/14 C07B 2200/05
Filing Date
2020-12-14
Application No.
17787113
Claims
14
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.